A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Recruiting now · Phase 3

Conditions studied: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications

In brief

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.

Key facts

Study ID

NCT03394365

Run by

Pierre Fabre Medicament

People needed

115

Starts

2017-12-29

Expected to finish

2030-08-01

Last updated by the study team

2026-07-31

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Prior SOT of kidney, liver, heart, lung, pancreas, small bowel, or any combination of these (C-SOT); or prior allogeneic HCT (C-HCT).
• A diagnosis of locally assessed, biopsy-proven EBV+ PTLD.
• Availability of appropriate partially HLA-matched and restricted tabelecleucel has been confirmed by the sponsor.
• Measurable, 18F-deoxyglucose (FDG)-avid (Deauville score ≥ 3) systemic disease using Lugano Classification response criteria by positron emission tomography (PET)-diagnostic computed tomography (CT), except when contraindicated or mandated by local practice, then magnetic resonance imaging (MRI) may be used. For participants with treated central nervous system (CNS) disease, a head CT and/or brain/spinal MRI as clinically appropriate will be required to follow CNS disease response per Lugano Classification response criteria.
• Treatment failure of rituximab or interchangeable commercially available biosimilar monotherapy (C-SOT-R or C-HCT) or rituximab plus any concurrent or sequentially administered chemotherapy regimen (C-SOT-R+C) for treatment of PTLD.
• Males and females of any age.
• Eastern Cooperative Oncology Group performance status ≤ 3 for participants aged ≥ 16 years; Lansky score ≥ 20 for participants < 16 years.
• For C-HCT only: If allogeneic HCT was performed as treatment for an acute lymphoid or myeloid malignancy, the underlying primary disease for which the participant underwent transplant must be in morphologic remission.
• Adequate organ function.
• Absolute neutrophil count ≥ 1000/μL, (C-SOT) or ≥ 500/μL (C-HCT), with or without cytokine support.
• Platelet count ≥ 50,000/μL, with or without transfusion or cytokine support. For C-HCT, platelet count < 50,000/μL but ≥ 20,000/μL, with or without transfusion support, is permissible if the participant has not had grade ≥ 2 bleeding in the prior 4 weeks (where grading of the bleeding is determined per the National Cancer Institute's Common Terminology Criteria for Adverse Events [CTCAE], version 5.0).
• Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin each < 5 × the upper limit of normal; however, ALT, AST, and total bilirubin each ≤ 10 × upper limit of normal is acceptable if the elevation is considered by the investigator to be due to EBV and/or PTLD involvement of the liver as long as there is no known evidence of significant liver dysfunction.
• Participant or participant's representative is willing and able to provide written informed consent.

You may not qualify if…

• Currently active Burkitt, T-cell, NK/T-cell lymphoma/LPD, Hodgkin, plasmablastic, transformed lymphoma, active hemophagocytic lymphohistiocytosis, or other malignancies requiring systemic therapy.
• Daily steroids of > 0.5 mg/kg prednisone or glucocorticoid equivalent, ongoing methotrexate, or extracorporeal photopheresis.
• Untreated CNS PTLD or CNS PTLD for which the participant is actively receiving CNS-directed chemotherapy (systemic or intrathecal) or radiotherapy at enrollment. NOTE: Participants with previously treated CNS PTLD may enroll if CNS-directed therapy is complete.
• Suspected or confirmed grade ≥ 2 graft-versus-host disease (GvHD) per the Center for International Blood and Marrow Transplant Research consensus grading system at enrollment.
• Ongoing or recent use of a checkpoint inhibitor agent (eg, ipilimumab, pembrolizumab, nivolumab) within 3 drug half-lives from the most recent dose to enrollment.
• For C-HCT: active adenovirus viremia.
• Need for vasopressor or ventilatory support.
• Antithymocyte globulin or similar anti-T cell antibody therapy ≤ 4 weeks prior to enrollment.
• Treatment with Epstein-Barr virus cytotoxic T lymphocytes or chimeric antigen receptor T cells directed against B cells within 8 weeks of enrollment (C-SOT or C-HCT), or unselected donor lymphocyte infusion within 8 weeks of enrollment (C-HCT only).
• Female who is breastfeeding or pregnant or female of childbearing potential or male with a female partner of childbearing potential unwilling to use a highly effective method of contraception.
• Inability to comply with study-related procedures.
• Any medical condition or organ system dysfunction that in the investigator';s opinion, could compromise the participant's safety or ability to complete the study.

Where it is running

• MD Anderson Cancer Center (Pediatrics and Adult) — Houston, Texas, United States (enrolling)
• The Royal Children's Hospital Melbourne (Pediatrics only) — Melbourne, Victoria, Australia (enrolling)
• Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (Adults and Pediatrics) — Columbus, Ohio, United States (enrolling)
• University of Texas Southwestern Medical Center - Children's Medical Center (Pediatrics only) — Dallas, Texas, United States (enrolling)
• The Children's Hospital at Westmead (Pediatrics only) — Westmead, New South Wales, Australia (enrolling)
• Royal Adelaide Hospital (Adults only) — Adelaide, South Australia, Australia (enrolling)
• Duke Cancer Institute (Adults and Pediatrics) — Durham, North Carolina, United States (enrolling)
• Cleveland Clinic Foundation (Adults and Pediatrics) — Cleveland, Ohio, United States (enrolling)
• Hospital of the University of Pennsylvania (Adults only) — Philadelphia, Pennsylvania, United States (enrolling)
• Baylor Scott and White Research Institute (Adults only) — Dallas, Texas, United States (enrolling)
• Loma Linda University Medical Center (Adults only) — Loma Linda, California, United States (enrolling)
• Ann & Robert H. Lurie Children's Hospital of Chicago (Adults and Pediatrics) — Chicago, Illinois, United States (enrolling)
• Westmead Hospital (Adults only) — Westmead, New South Wales, Australia (enrolling)
• Loyola University Medical Center (Adults and Pediatrics) — Maywood, Illinois, United States (enrolling)
• MedStar Georgetown University Hospital (Adults and Pediatrics) — Washington D.C., District of Columbia, United States (enrolling)
• Dana Farber Cancer Institute, Brigham and Women's Hospital (Adults and Pediatrics) — Boston, Massachusetts, United States (enrolling)
• Washington University School of Medicine (Adults only) — St Louis, Missouri, United States (enrolling)
• Children's Hospital Los Angeles, Div. of Research Immunology/BMT (Adults and Pediatrics) — Los Angeles, California, United States (enrolling)
• University of Miami/Jackson Memorial Hospital (Adults only) — Miami, Florida, United States (enrolling)
• Oregon Health and Science University Physicians Pavilion (Adults and Pediatrics) — Portland, Oregon, United States (enrolling)
• The Children's Hospital of Philadelphia Oncology Division, Blood & Marrow Transplant Section (Pediatrics) — Philadelphia, Pennsylvania, United States (enrolling)
• Vanderbilt University Medical Center Henry-Joyce Cancer Clinic (Adults and Pediatrics) — Nashville, Tennessee, United States (enrolling)
• Arthur M. Blank Hospital (Pediatrics) — Atlanta, Georgia, United States (enrolling)
• Carolinas Medical Center/Levine Children's Hospital (Adults and Pediatrics) — Charlotte, North Carolina, United States (enrolling)
• Fiona Stanley Hospital (Adults only) — Murdoch, Western Australia, Australia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.